Status:
COMPLETED
Treatment and Exacerbation in COPD Subjects
Lead Sponsor:
AstraZeneca
Conditions:
Comparative Effectiveness Study
Eligibility:
All Genders
Brief Summary
This is a study comparing the effects of ICS containing treatments in patients with chronic obstructive pulmonary disease (COPD) in a real world setting, using the UK Clinical Practice Research Datali...
Detailed Description
Background/Rationale: For people with chronic obstructive pulmonary disease (COPD), standard maintenance inhaler treatments consist of inhaled corticosteroids (ICS) and long acting bronchodilators (p...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- \- All adult COPD patients aged ≥40, with a smoking history, incident prescription of a study therapy, and research acceptable data.
- Exclusion criteria:
- \- Any subjects with less than 12 months of UTS data prior to index date.
Exclusion
Key Trial Info
Start Date :
June 9 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 30 2019
Estimated Enrollment :
60243 Patients enrolled
Trial Details
Trial ID
NCT03375450
Start Date
June 9 2017
End Date
August 30 2019
Last Update
September 14 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
London, United Kingdom